ClinicalTrials.gg
RecruitingNCT07184814CAPTAINUpdated Sep 22, 2025

Clinical Features and Prognosis of Takayasu's Arteritis With Pulmonary Arteries Involvement

An observational study in Takayasu Arteritis With Pulmonary Artery Involvement and Pulmonary Arterial Hypertension Associated With Connective Tissue Disease, sponsored by China-Japan Friendship Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-22.

Sponsored by China-Japan Friendship Hospital · Observational

How we know

From the registry’s dates

  • Started Jan 2016; still recruiting 10 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 27 studies in Connective Tissue Diseases with a site in China — 13 open to participants now, 18 under way, 7 of them phase 3. Connective Tissue Diseases · China.

Started
2016
the only one that year
Observational
5 of 27
2 open now
Primary completion
2026-12
later than 11 of 17 live
Registered
27th of 27
by date

Among the 27 studies in Connective Tissue Diseases with a site in China, this one is the only one that started in 2016, is one of 5 observational ones, reaches primary completion later than 11 of the 17 other live ones, and was the 27th registered.

Connective Tissue Diseases

192 studies on the registry are indexed under Connective Tissue Diseases; 56 are open to participants now.

Browse Connective Tissue Diseases studies →

Open to participants now

13 of the 27 studies in Connective Tissue Diseases with a site in China are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 43 Connective Tissue Diseases studies recruiting now, 30 (70%) set no upper age limit and 7 (16%) stop at 75 or younger; 5 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Connective Tissue Diseases with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to identify the clinical features, management pattern and long-term outcomes of patients with pulmonary arteries involvement in Takayasu's arteritis (TAK-PAI).

Read the detailed description

The present study intends to conduct a prospective analysis of the clinical data in TAK patients in order to:

  1. describe the clinical characteristics and current status of multimodal treatment in patients with TAK-PAI, thereby enhancing the understanding of TAK-PAI;
  2. to investigate the risk factors for mortality in patients with TAK-PAI, so as to promote early intervention and reduce mortality.
  3. explore factors associated with pulmonary hypertention (PH) in patients with TAK-PAI, so as to facilitate the early identification of patients who may develop PH.
03

Conditions studied

  • Takayasu Arteritis With Pulmonary Artery Involvement
  • Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

TAK patients hospitalized at the China-Japan Friendship Hospital, Beijing Anzhen Hospital and Beijing Chaoyang Hospital.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hospitalized between Jan 1, 2016 and Dec 31, 2026
  • Diagnosed with TAK according to the modified Ishikawa criteria and/or 1990 American College of Rheumatology criteria and/or 2022 ACR/EULAR criteria
  • Diagnosed with pulmonary artery involvement using computed tomography pulmonary angiography or transcatheter pulmonary angiography
  • Patients without aortic or primary branch involvement who nonetheless exhibited both clinical features and computed tomography-confirmed evidence of pulmonary artery involvement (PAI), after exclusion of other diseases causing pulmonary artery stenosis or occlusion

Exclusion criteria

Exclusion Criteria:

  • Patients with PAI caused by non-TAK diseases such as other types of vasculitis, fibrosing mediastinitis, pulmonary artery sarcoma, pulmonary sarcoidosis or chronic thromboembolic pulmonary hypertension
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • TAK-PAI group
06

What researchers measure

Primary outcomes

  1. All-cause death

    Time frame: At 3 months, 6 months, and annually thereafter following enrollment, until December 31, 2026.

Secondary outcomes

  1. Six-minute walk distance

    Time frame: At 3 months, 6 months, and annually thereafter following enrollment, until December 31, 2026

  2. WHO functional class

    Time frame: At 3 months, 6 months, and annually thereafter following enrollment, until December 31, 2026.

  3. N-terminal pro-brain natriuretic peptide level

    Time frame: At 3 months, 6 months, and annually thereafter following enrollment, until December 31, 2026

Other outcomes

  1. Mean pulmonary arterial pressure assessed by right heart catheterization

    Hemodynamic parameters assessed by right heart catheterization in patients with pulmonary hypertension.

    Time frame: At 3 months, 6 months, and annually thereafter following enrollment, until December 31, 2026.

  2. Pulmonary vascular resistance assessed by right heart catheterization

    Hemodynamic parameters assessed by right heart catheterization in patients with pulmonary hypertension.

    Time frame: At 3 months, 6 months, and annually thereafter following enrollment, until December 31, 2026.

  3. Cardiac output assessed by right heart catheterization

    Hemodynamic parameters assessed by right heart catheterization in patients with pulmonary hypertension.

    Time frame: At 3 months, 6 months, and annually thereafter following enrollment, until December 31, 2026.

  4. Cardiac index assessed by right heart catheterization

    Hemodynamic parameters assessed by right heart catheterization in patients with pulmonary hypertension.

    Time frame: At 3 months, 6 months, and annually thereafter following enrollment, until December 31, 2026.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Zheng S, Li Y, Liu Z, Chen Y, Song Y, Zhang S, Xie W, Zhai Z. Pulmonary hypertension in Takayasu arteritis with pulmonary artery involvement: risk factors and impact on mortality. BMJ Open Respir Res. 2026 Apr 1;13(1):e003854. doi: 10.1136/bmjresp-2025-003854. PubMed 41922023 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2016 (actual). Primary completion is estimated for Dec 2026, 131 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2025
First posted
Sep 22, 2025
StartActual
Jan 1, 2016
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Sep 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07184814
Responsible party
Wanmu Xie (Director, Department of Integrative Pulmonary Medicine, China-Japan Friendship Hospital) — Principal investigator
First posted
Sep 22, 2025
Start date
Jan 1, 2016
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Sep 22, 2025

Study contacts

Wanmu Xie, Doctor
Contact
xiewanmu@126.com
15611734410

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion